Paper32276005
Engineering peptide-targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacy.
Kim B and 6 others. J Control Release, 2020. Cited by 56 papers, by iCite.
Cite this record
ConductScience Library. Engineering peptide-targeted liposomal nanoparticles optimized for improved selectivity for HER2-positive breast cancer cells to achieve enhanced in vivo efficacy. Papers, record 32276005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32276005
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Nanoparticles | Major topic |
| Animals | |
| Cell Line, Tumor | |
| Doxorubicin | |
| Drug Delivery Systems | |
| Female | |
| Humans | |
| Mice | |
| Peptides | |
| Reproducibility of Results |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R33 CA206922 | NCI NIH HHS | United States | R33CA206922 | PubMed and NIH |
Source NIH RePORTER
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27196779 | Dual Carfilzomib and Doxorubicin-Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma. | Mol Cancer Ther | 2016 | https://conductscience.org/library/papers/27196779 | PubMed |
| 2 | 23116010 | Multivalent ligand: design principle for targeted therapeutic delivery approach. | Ther Deliv | 2012 | https://conductscience.org/library/papers/23116010 | PubMed |
| 3 | 24003770 | Enhanced cellular uptake of peptide-targeted nanoparticles through increased peptide hydrophilicity and optimized ethylene glycol peptide-linker length. | ACS Nano | 2013 | https://conductscience.org/library/papers/24003770 | PubMed |
| 4 | 18481173 | PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity. | Breast Cancer Res Treat | 2009 | https://conductscience.org/library/papers/18481173 | PubMed |
| 5 | 31473250 | Optimizing design parameters of a peptide targeted liposomal nanoparticle in an in vivo multiple myeloma disease model after initial evaluation in vitro. | J Control Release | 2019 | https://conductscience.org/library/papers/31473250 | PubMed |
| 6 | 18937508 | Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. | Bioconjug Chem | 2008 | https://conductscience.org/library/papers/18937508 | PubMed |
| 7 | 23841107 | Functionalized liposome purification via Liposome Extruder Purification (LEP). | Analyst | 2013 | https://conductscience.org/library/papers/23841107 | PubMed |
| 8 | 23330947 | Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. | Br J Pharmacol | 2013 | https://conductscience.org/library/papers/23330947 | PubMed |
| 9 | 30361524 | Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. | Br J Cancer | 2018 | https://conductscience.org/library/papers/30361524 | PubMed |
| 10 | 17611206 | Trastuzumab--mechanism of action and use in clinical practice. | N Engl J Med | 2007 | https://conductscience.org/library/papers/17611206 | PubMed |
| 11 | 18272481 | Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. | Proc Natl Acad Sci U S A | 2008 | https://conductscience.org/library/papers/18272481 | PubMed |
| 12 | 26149286 | The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment. | ACS Nano | 2015 | https://conductscience.org/library/papers/26149286 | PubMed |
| 13 | 10606988 | Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice. | Clin Exp Immunol | 2000 | https://conductscience.org/library/papers/10606988 | PubMed |
| 14 | 23776619 | Targeted drug delivery systems mediated by a novel Peptide in breast cancer therapy and imaging. | PLoS One | 2013 | https://conductscience.org/library/papers/23776619 | PubMed |
| 15 | 29751334 | Treatment of advanced HER2-positive breast cancer: 2018 and beyond. | Cancer Treat Rev | 2018 | https://conductscience.org/library/papers/29751334 | PubMed |
| 16 | 17579068 | Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. | J Immunol | 2007 | https://conductscience.org/library/papers/17579068 | PubMed |
| 17 | 26295142 | Improved Peptide-Targeted Liposome Design Through Optimized Peptide Hydrophilicity, Ethylene Glycol Linker Length, and Peptide Density. | J Biomed Nanotechnol | 2015 | https://conductscience.org/library/papers/26295142 | PubMed |
| 18 | 12360278 | Ligand-targeted therapeutics in anticancer therapy. | Nat Rev Cancer | 2002 | https://conductscience.org/library/papers/12360278 | PubMed |
| 19 | 1359541 | Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. | Proc Natl Acad Sci U S A | 1992 | https://conductscience.org/library/papers/1359541 | PubMed |
| 20 | 21406401 | Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. | Cancer Res | 2011 | https://conductscience.org/library/papers/21406401 | PubMed |
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 56 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42974396 | Identification of B-cell maturation antigen (BCMA)-targeting peptides and selective drug delivery to multiple myeloma using peptide-targeted DM1 prodrug-loaded nanoparticles. | Nanoscale Adv | 2026 | https://conductscience.org/library/papers/42974396 | PubMed |
| 42353096 | 17-DMAG-Loaded HER2-Targeted Extracellular Vesicles Induce PARP/Caspase3-Mediated Apoptosis in Gastric Carcinoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42353096 | PubMed |
| 41660126 | Advancing precision tumor therapy: Progress in targeted delivery of peptide-based nanomaterials from microenvironment to organelles. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/41660126 | PubMed |
| 40838213 | Innovative nanocarriers: Synthetic and biomimetic strategies for enhanced drug delivery. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/40838213 | PubMed |
| 40747717 | Role of miRNA‑214‑3p in cancer (Review). | Oncol Rep | 2025 | https://conductscience.org/library/papers/40747717 | PubMed |
| 40584785 | Developing the Strategy to Use Silk Spheres for Efficient, Targeted Delivery of Oligonucleotide Therapeutics to Cancer Cells. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/40584785 | PubMed |
| 40176316 | Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics. | ACS Nano | 2025 | https://conductscience.org/library/papers/40176316 | PubMed |
| 40094065 | Advances in nanotechnology for targeting cancer-associated fibroblasts: A review of multi-strategy drug delivery and preclinical insights. | APL Bioeng | 2025 | https://conductscience.org/library/papers/40094065 | PubMed |
| 39271060 | Combination non-targeted and sGRP78-targeted nanoparticle drug delivery outperforms either component to treat metastatic ovarian cancer. | J Control Release | 2024 | https://conductscience.org/library/papers/39271060 | PubMed |
| 39100472 | Albumin incorporation into recognising layer of HER2-specific magnetic nanoparticles as a tool for optimal targeting of the acidic tumor microenvironment. | Heliyon | 2024 | https://conductscience.org/library/papers/39100472 | PubMed |
| 39050885 | Recent advanced lipid-based nanomedicines for overcoming cancer resistance. | Cancer Drug Resist | 2024 | https://conductscience.org/library/papers/39050885 | PubMed |
| 38961887 | Peptide Conjugated Boron Neutron Capture Therapy for Enhanced Tumor Targeting. | Nanotheranostics | 2024 | https://conductscience.org/library/papers/38961887 | PubMed |
| 38660023 | EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/38660023 | PubMed |
| 38126905 | Nanotechnology Applications in Breast Cancer Immunotherapy. | Small | 2024 | https://conductscience.org/library/papers/38126905 | PubMed |
| 37686984 | Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics. | Nanomaterials (Basel) | 2023 | https://conductscience.org/library/papers/37686984 | PubMed |
| 37633875 | Synthesis Folate-linked Chitosan-coated Quetiapine/BSA Nano-Carriers as the Efficient Targeted Anti-Cancer Drug Delivery System. | Mol Biotechnol | 2024 | https://conductscience.org/library/papers/37633875 | PubMed |
| 36794282 | Recent advances in peptide-based therapeutic strategies for breast cancer treatment. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/36794282 | PubMed |
| 36632508 | Functionalized liposomes for targeted breast cancer drug delivery. | Bioact Mater | 2023 | https://conductscience.org/library/papers/36632508 | PubMed |
| 36499301 | The Impact of Nanobody Density on the Targeting Efficiency of PEGylated Liposomes. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36499301 | PubMed |
| 36374573 | Fn14-Directed DART Nanoparticles Selectively Target Neoplastic Cells in Preclinical Models of Triple-Negative Breast Cancer Brain Metastasis. | Mol Pharm | 2023 | https://conductscience.org/library/papers/36374573 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32276005
GET https://conductscience.org/api/papers/v1/32276005/references?page=2